title: Thrombophilia and pregnancy complications.
abstract: OBJECTIVE
  This systematic review examines the strength of the association between thrombophilia and recurrent pregnancy loss and other serious obstetric complications. Study design Electronic databases and manual bibliography searches were used to identify studies evaluating the association between thrombophilia and pregnancy loss, preeclampsia, fetal growth retardation, and placental abruption.
  
  
  RESULTS
  Thrombophilic disorders are associated with an increased risk of fetal loss in the majority of case control and cohort studies. The risk is increased throughout pregnancy, but may be higher in the second and third trimester. The common pathologic finding of placental infarction suggests unexplained fetal loss may result from uteroplacental insufficiency and thrombosis. Thrombophilic disorders are not consistently associated with preeclampsia, fetal growth retardation, or placental abruption. Preliminary data suggest prophylactic anticoagulation may improve outcome in thrombophilic women with unexplained recurrent fetal loss.
  
  
  CONCLUSIONS
  Women with thrombophilia have an increased risk of pregnancy loss and possibly other serious obstetric complications, although definition of the magnitude of risk will require prospective longitudinal studies. Preliminary data suggesting prophylactic anticoagulation may improve gestational outcome provide a rationale for prospective randomized trials in thrombophilic women with unexplained recurrent fetal loss.
authors.affiliation: Division of Hematology/Medical Oncology, Oregon Health and Science University, 3181 SE Sam Jackson Park Road, Portland, OR 97239, USA. kujovich@ohsu.edu
authors.forename: Jody L
authors.initials: JL
authors.lastname: Kujovich
mesh_terms: D000026:Abortion, Habitual / Q000453:epidemiology*; D017984:Enoxaparin / Q000627:therapeutic use; D005165:Factor V / Q000235:genetics; D005260:Female; D005317:Fetal Growth Retardation / Q000453:epidemiology; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D011225:Pre-Eclampsia / Q000453:epidemiology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000453:epidemiology*; D011250:Pregnancy Complications, Hematologic / Q000453:epidemiology*; D011256:Pregnancy Outcome; D019851:Thrombophilia / Q000188:drug therapy / Q000453:epidemiology* / Q000235:genetics
chemical_list: D017984:Enoxaparin; D005343:Fibrinolytic Agents; C095381:factor V Leiden; D005165:Factor V